Loading...
XKRX
145020
Market cap1.80bUSD
Jul 10, Last price  
240,500.00KRW
1D
1.91%
1Q
-5.69%
Jan 2017
-25.10%
IPO
35.57%
Name

Hugel Inc

Chart & Performance

D1W1MN
XKRX:145020 chart
P/E
19.63
P/S
6.51
EPS
12,249.57
Div Yield, %
Shrs. gr., 5y
0.74%
Rev. gr., 5y
15.03%
Revenues
425.11b
+13.96%
204,567,625,000211,038,348,000231,859,108,000281,675,135,000319,699,941,000373,046,886,000425,110,000,000
Net income
140.87b
+3.72%
44,612,095,00041,992,095,00057,730,176,00057,331,826,00093,076,069,000135,813,577,000140,871,771,000
CFO
150.06b
+0.68%
76,994,955,00074,302,498,00085,940,035,00080,626,442,000117,705,306,000149,050,889,000150,058,741,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hugel, Inc. is a biopharmaceutical firm headquartered in Chuncheon-si, South Korea, with a presence both domestically and internationally. The company specializes in the development and manufacturing of diverse medical solutions. A primary product is its Botulinum Toxin, presented as a clear glass vial containing a white, injectable dry powder. This therapeutic is prescribed for several conditions: treating essential eyelid spasms in adults over 18; ameliorating severe frown lines linked to corrugator and/or procerus muscle activity in adults aged 18 to 65; managing upper limb spasticity following a stroke; and correcting dynamic equinus foot deformity in children with cerebral palsy aged over 2. Furthermore, it aids in improving the lateral canthal lines (crow's feet) caused by orbicularis oculi muscle activity in adults between 19 and 65. This product is marketed under various labels, including Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. Hugel also provides hyaluronic acid dermal fillers, known as Dermalax and The Chaeum; cosmetic products under the Wellage brand; and medical devices distributed as BlueRose. Hugel, Inc. commenced operations in 2001.
IPO date
Dec 24, 2015
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT